Relmada Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell RLMD and other ETFs, options, and stocks.About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications.
CEOSergio Traversa
CEOSergio Traversa
Employees17
Employees17
HeadquartersCoral Gables, Florida
HeadquartersCoral Gables, Florida
Founded2012
Founded2012
Employees17
Employees17
RLMD Key Statistics
Market cap297.37M
Market cap297.37M
Price-Earnings ratio-2.26
Price-Earnings ratio-2.26
Dividend yield—
Dividend yield—
Average volume1.14M
Average volume1.14M
High today$4.59
High today$4.59
Low today$4.01
Low today$4.01
Open price$4.22
Open price$4.22
Volume1.57M
Volume1.57M
52 Week high$5.12
52 Week high$5.12
52 Week low$0.2404
52 Week low$0.2404
Stock Snapshot
With a market cap of 297.37M, Relmada Therapeutics(RLMD) trades at $4.04. The stock has a price-to-earnings ratio of -2.26.
On 2025-12-14, Relmada Therapeutics(RLMD) stock moved within a range of $4.01 to $4.59. With shares now at $4.04, the stock is trading +0.7% above its intraday low and -11.9% below the session's peak.
Trading activity shows a volume of 1.57M, compared to an average daily volume of 1.14M.
The stock's 52-week range extends from a low of $0.24 to a high of $5.12.
The stock's 52-week range extends from a low of $0.24 to a high of $5.12.
People also own
Based on the portfolios of people who own RLMD. This list is generated using Robinhood data, and it’s not a recommendation.